EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

MVB Maturation Responsive to KRAS G12D /TP53 R175H Co‐mutations Fuels Extracellular Vesicle‐hypersecretion Phenotype to Aggravate Lymphangiogenesis and Lymphatic Metastasis

Jiabin Yang, Yuming Luo, Yu Zhou, Mingjie An, Mingrui Pang, Zhihua Li, Qingyu Xie, Hanhao Zheng, Zhou Fang, Yao Kong, Chao Yu, Yan Lin und 5 weitere

Journal of Extracellular Vesicles · 2026

DOI: 10.1002/jev2.70383 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Extracellular Vesicles, 2026. Verfasst von Jiabin Yang und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pancreatic Surgery, Department of General Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Sout…. Hauptthemen laut MEDLINE: Lymphangiogenesis, Extracellular Vesicles, Lymphatic Metastasis, Tumor Suppressor Protein p53. Die Arbeit nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China, Guangdong Basic and Applied Basic Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KRAS G12D /TP53 R175H mutations are hallmarks of malignant tumor progression and are associated with lymph node (LN) metastasis in solid tumor. Nevertheless, the mechanisms underlying KRAS G12D /TP53 R175H co‐mutation‐mediated LN metastasis remain unclear. Herein, we developed KRAS G12D /TP53 R175H mutation‐related orthotopic xenograft models and demonstrated that KRAS G12D /TP53 R175H co‐mutation promotes the lymphangiogenesis and LN metastasis. FUS is identified by next generation sequencing to be upregulated in tumor tissues harbouring KRAS G12D /TP53 R175H co‐mutation across multi‐center cohorts, wherein KRAS G12D ‐mediated phosphorylation of TP53 R175H promotes FUS transcriptional activation. Functionally, FUS‐mediated extracellular vesicle (EV) promotes lymphangiogenesis and LN metastasis in vitro and in vivo . Mechanistically, upon KRAS G12D /TP53 R175H co ‑ mutation, FUS regulated circSCARNA10 biosynthesis and promotes EVs secretion by stabilizing RAB3B mRNA, leading to VEGFR3 transcription in lymphatic endothelial cells to trigger lymphangiogenesis and LN metastasis. Blockade of FUS inhibits LN metastasis in Kras G12D/+ Trp53 R172H/+ Pdx‐1‐Cre (KPC) mice model. Clinically, detecting circSCARNA10 in serum‐EVs exhibited higher diagnostic efficiency compared with traditional biomarkers, carcinoembryonic antigen (CEA) and carbohydrate antigen 19‐9 (CA19‐9) in distinguishing LN metastasis. Collectively, we highlight the precise mechanisms by which KRAS G12D /TP53 R175H co‐mutation mediates EV secretion to trigger LN metastasis, providing a potential therapeutic target for KRAS G12D /TP53 R175H co‐mutation ‐ driven LN metastasis.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

LymphangiogenesisExtracellular VesiclesLymphatic MetastasisTumor Suppressor Protein p53Proto-Oncogene Proteins p21(ras)AnimalsHumansMiceMutationCell Line, Tumor

Stichwörter der Autor:innen

KRASG12DTP53R175Hextracellular vesicleslymphangiogenesislymphatic metastasis

Substanzen

Tumor Suppressor Protein p53Proto-Oncogene Proteins p21(ras)KRAS protein, human

Autor:innen und Institutionen

  • Department of Pancreatic Surgery, Department of General Surgery, Guangdong Provincial People's Hospital (Guangdong Academy of Medical Sciences), Southern Medical University, Guangzhou, Guangdong, PR China.
  • Department of Urology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, PR China.
  • Guangdong Provincial Key Laboratory of Malignant Tumor Epigenetics and Gene Regulation, State Key Laboratory of Oncology in South China, Sun Yat-sen Memorial Hospital, Guangzhou, Guangdong, PR China.
  • Department of Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, Guangdong, PR China.
  • Department of Medical Ultrasonics, The Eighth Affiliated Hospital of Sun Yat-Sen University, Shenzhen, Guangdong, PR China.

ORCID-Profile: Changhao Chen, Rufu Chen

Förderung

  • National Key Research and Development Program of China
  • National Natural Science Foundation of China
  • Guangdong Basic and Applied Basic Research Foundation
  • Medical Scientific Research Foundation of Guangdong Province
  • Science and Technology Program of Guangzhou
  • Precision Diagnosis and Treatment Center for Liver
  • Pancreas Diseases Project of Guangdong Provincial People's Hospital
  • National Postdoctoral Innovation Talent Support Program of China

Zitieren

APA

Yang, J., Luo, Y., Zhou, Y., An, M., Pang, M., Li, Z., Xie, Q., Zheng, H., Fang, Z., Kong, Y., Yu, C., Lin, Y., Zhang, D., Cao, B., Zhong, H., Chen, C., & Chen, R. (2026). MVB Maturation Responsive to KRAS G12D /TP53 R175H Co‐mutations Fuels Extracellular Vesicle‐hypersecretion Phenotype to Aggravate Lymphangiogenesis and Lymphatic Metastasis. Journal of Extracellular Vesicles. https://doi.org/10.1002/jev2.70383

Vancouver

Yang J, Luo Y, Zhou Y, An M, Pang M, Li Z, et al. MVB Maturation Responsive to KRAS G12D /TP53 R175H Co‐mutations Fuels Extracellular Vesicle‐hypersecretion Phenotype to Aggravate Lymphangiogenesis and Lymphatic Metastasis. Journal of Extracellular Vesicles. 2026. doi:10.1002/jev2.70383

BibTeX
@article{Yang2026,
  author = {Yang, Jiabin and Luo, Yuming and Zhou, Yu and An, Mingjie and Pang, Mingrui and Li, Zhihua and Xie, Qingyu and Zheng, Hanhao and Fang, Zhou and Kong, Yao and Yu, Chao and Lin, Yan and Zhang, Dingwen and Cao, Bingxin and Zhong, Haoming and Chen, Changhao and Chen, Rufu},
  title = {MVB Maturation Responsive to KRAS G12D /TP53 R175H Co‐mutations Fuels Extracellular Vesicle‐hypersecretion Phenotype to Aggravate Lymphangiogenesis and Lymphatic Metastasis},
  journal = {Journal of Extracellular Vesicles},
  year = {2026},
  doi = {10.1002/jev2.70383}
}
Kostenlos starten →